Under‐representation of racial minorities in prostate cancer studies submitted to the US Food and Drug Administration to support potential marketing approval, 1993‐2013

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|120|19|3025-3032

ISSN： 0008-543x

Source： CANCER, Vol.120, Iss.19, 2014-10, pp. : 3025-3032

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Primary human papillomavirus screening for cervical cancer in the United States—US Food and Drug Administration approval, clinical trials, and where we are today

By  

CANCER CYTOPATHOLOGY, Vol. 122, Iss. 10, 2014-10 ,pp. : 720-729

John Wiley & Sons Inc

Access to resources Recommend Favorite

Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration

By  

CANCER, Vol. 121, Iss. 10, 2015-05 ,pp. : 1688-1693

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pain palliation measurement in cancer clinical trials: The US Food and Drug Administration perspective

By  

CANCER, Vol. 120, Iss. 5, 2014-03 ,pp. : 761-767

John Wiley & Sons Inc

Access to resources Recommend Favorite

Liver injury with novel oral anticoagulants: assessing post‐marketing reports in the US Food and Drug Administration adverse event reporting system

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 2, 2015-08 ,pp. : 285-293

John Wiley & Sons Inc

Access to resources Recommend Favorite

Generic drug approval: A US perspective

By Nagori B.P.   Mathur V.   Garg S.  

Current Medical Research and Opinion, Vol. 27, Iss. 3, 2011-03 ,pp. : 541-545

Informa Healthcare

Access to resources Recommend Favorite